(Q39380926)

English

Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

11 September 2017

Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100. (English)

1 reference

Europe PubMed Central

PMC publication ID

11 September 2017

1 reference

ChEBI release 2020-05-28

1 reference

ChEBI release 2020-05-28

Gerhardt Attard

13

1 reference

Europe PubMed Central

PMC publication ID

11 September 2017

Suzanne Carreira

object named as

Suzanne Carreira

8

0 references

object named as

Wiebke Arlt

10

0 references

9

object named as

Jane Goodall

1 reference

Europe PubMed Central

PMC publication ID

11 September 2017

author name string

Juliet Richards

1

1 reference

Europe PubMed Central

PMC publication ID

11 September 2017

Ai Chiin Lim

2

1 reference

Europe PubMed Central

PMC publication ID

11 September 2017

Colin W Hay

3

1 reference

Europe PubMed Central

PMC publication ID

11 September 2017

Angela E Taylor

4

1 reference

Europe PubMed Central

PMC publication ID

11 September 2017

Anna Wingate

5

1 reference

Europe PubMed Central

PMC publication ID

11 September 2017

Karolina Nowakowska

6

1 reference

Europe PubMed Central

PMC publication ID

11 September 2017

Carmel Pezaro

7

1 reference

Europe PubMed Central

PMC publication ID

11 September 2017

Iain J McEwan

11

1 reference

Europe PubMed Central

PMC publication ID

11 September 2017

Johann S de Bono

12

1 reference

Europe PubMed Central

PMC publication ID

11 September 2017

language of work or name

0 references

publication date

12 March 2012

1 reference

Europe PubMed Central

PMC publication ID

11 September 2017

Cancer Research

1 reference

Europe PubMed Central

PMC publication ID

11 September 2017

72

1 reference

Europe PubMed Central

PMC publication ID

11 September 2017

9

1 reference

Europe PubMed Central

PMC publication ID

11 September 2017

2176-2182

1 reference

Europe PubMed Central

PMC publication ID

11 September 2017

Direct regulation of androgen receptor activity by potent CYP17 inhibitors in prostate cancer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4281708

11 September 2017

Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4281708

11 September 2017

Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4281708

11 September 2017

Abiraterone and increased survival in metastatic prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4281708

11 September 2017

Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4281708

11 September 2017

Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4281708

11 September 2017

Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4281708

11 September 2017

Development of a second-generation antiandrogen for treatment of advanced prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4281708

11 September 2017

Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4281708

11 September 2017

Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4281708

11 September 2017

Androgenic activity of synthetic progestins and spironolactone in androgen-sensitive mouse mammary carcinoma (Shionogi) cells in culture

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4281708

11 September 2017

Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4281708

14 September 2017

Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4281708

25 September 2017

Novel Steroidal Inhibitors of Human Cytochrome P45017.alpha.-Hydroxylase-C17,20-lyase): Potential Agents for the Treatment of Prostatic Cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4281708

15 June 2018

Antiandrogen bicalutamide promotes tumor growth in a novel androgen-dependent prostate cancer xenograft model derived from a bicalutamide-treated patient

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4281708

21 August 2018

Pharmacokinetics of eplerenone after single and multiple dosing in subjects with and without renal impairment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4281708

21 August 2018

Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4281708

21 August 2018

Clinical and Biochemical Consequences of CYP17A1 Inhibition with Abiraterone Given with and without Exogenous Glucocorticoids in Castrate Men with Advanced Prostate Cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4281708

2 December 2018

Identifiers

10.1158/0008-5472.CAN-11-3980

1 reference

Europe PubMed Central

PMC publication ID

11 September 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

11 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

11 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39380926&oldid=1674336720"